Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney collecting ducts. This triggers a cascade that increases cyclic AMP, causing aquaporin‑2 channels to move to the cell surface and allow more water to be reabsorbed, concentrating urine. In blood vessels, V2 activation releases stored clotting factors, improving haemostasis.

The dose of Minirin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and response to therapy. Dosage adjustments are made according to clinical monitoring of urine output, serum sodium and, for bleeding disorders, factor levels. No fixed regimen is provided here.

Safety data for desmopressin acetate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue that selectively targets V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin (pitressin). Compared with other ADH analogues, desmopressin provides a more predictable antidiuretic response and the added benefit of raising clotting factor levels, making it useful for certain bleeding disorders.

Store Minirin nasal spray at room temperature, preferably below 25 °C (77 °F). Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the spray tip remains clean and uncapped when not in use.

Minirin is delivered as a metered‑dose nasal spray. The patient should gently blow the nose, insert the tip into one nostril, and press the actuator to release the prescribed number of sprays, usually one spray per nostril. The dose may be repeated in the other nostril if directed by the prescriber. Avoid swallowing the spray.

The most serious risks include severe hyponatremia, which can lead to seizures, confusion or coma, and water intoxication resulting in pulmonary edema. Patients should be monitored for rapid weight gain, headache, nausea, or neurological changes, and serum sodium should be checked regularly, especially in the elderly or those on diuretics.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin or any component of the formulation, uncontrolled hyponatremia, severe renal impairment, or chronic water intoxication. Caution is also advised for patients with uncontrolled hypertension, heart failure, or those taking other antidiuretic agents without medical supervision.